摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]-3-chloro-N-methylbenzamide

中文名称
——
中文别名
——
英文名称
4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]-3-chloro-N-methylbenzamide
英文别名
——
4-[4-[[(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undecan-9-yl]methyl]phenoxy]-3-chloro-N-methylbenzamide化学式
CAS
——
化学式
C34H45ClN4O5
mdl
——
分子量
625.2
InChiKey
GSOUSLYJSFQYEI-LOYHVIPDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.8
  • 重原子数:
    44
  • 可旋转键数:
    10
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    111
  • 氢给体数:
    3
  • 氢受体数:
    6

文献信息

  • Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
    申请人:Takaoka Yoshikazu
    公开号:US20050267114A1
    公开(公告)日:2005-12-01
    Compounds represented by formula (I) (wherein all of the symbols have the same meanings as defined in specification.), quaternary ammonium salts thereof, N-oxides thereof or salts thereof. The compounds represented by formula (I) are used for prevention and/or treatment of various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, chronic rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis and the like), immunologic diseases (autoimmune diseases, transplant rejection, immunosuppression, psoriasis, multiple sclerosis and the like), human immunodeficiency virus (acquired immunodeficiency syndrome and the like), allergic diseases (atopic dermatitis, nettle rash, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis and the like), ischemia-reperfusion injury, acute respiratory distress syndrome, shock accompanied by bacterial infection, diabetes mellitus, or metastasis and the like.
    化合物的化学式为(I)(其中所有符号的含义与规范中定义的相同),以及其季铵盐、N-氧化物或盐。式(I)所代表的化合物用于预防和/或治疗各种炎症性疾病(哮喘、肾炎、肾病、肝炎、关节炎、慢性类风湿性关节炎、鼻炎、结膜炎、溃疡性结肠炎等)、免疫性疾病(自身免疫疾病、移植排斥、免疫抑制、银屑病、多发性硬化症等)、人类免疫缺陷病毒(获得性免疫缺陷综合症等)、过敏性疾病(特应性皮炎、荨麻疹、过敏性支气管肺曲霉病、过敏性嗜酸性胃肠炎等)、缺血再灌注损伤、急性呼吸窘迫综合症、伴有细菌感染的休克、糖尿病或转移等。
  • TRIAZASPIRO 5.5 UNDECANE DERIVATIVES AND DRUGS COMPRISI NG THE SAME AS THE ACTIVE INGREDIENT
    申请人:ONO PHARMACEUTICAL CO., LTD.
    公开号:EP1541574A1
    公开(公告)日:2005-06-15
    Compounds represented by formula (I) (wherein all of the symbols have the same meanings as defined in specification.), quaternary ammonium salts thereof, N-oxides thereof or salts thereof. The compounds represented by formula (I) are used for prevention and/or treatment of various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, chronic rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis and the like), immunologic diseases (autoimmune diseases, transplant rejection, immunosuppression, psoriasis, multiple sclerosis and the like), human immunodeficiency virus (acquired immunodeficiency syndrome and the like), allergic diseases (atopic dermatitis, nettle rash, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis and the like), ischemia-reperfusion injury, acute respiratory distress syndrome, shock accompanied by bacterial infection, diabetes mellitus, or metastasis and the like.
    式 (I) 所代表的化合物(其中所有符号的含义与说明书中的定义相同。 (其中所有符号的含义与说明书中定义的相同)、其季铵盐、其 N-氧化物或其盐。式 (I) 所代表的化合物可用于预防和/或治疗各种炎症性疾病(哮喘、肾炎、肾病、肝炎、关节炎、慢性类风湿性关节炎、鼻炎、结膜炎、溃疡性结肠炎等)、免疫性疾病(自身免疫性疾病、移植排斥、免疫抑制、牛皮癣、多发性硬化等)、人类免疫缺陷病毒(获得性免疫缺陷综合征等)、过敏性疾病(特应性皮炎、荨麻疹、过敏性支气管肺曲霉病、过敏性嗜酸性粒细胞性胃肠炎等)、缺血再灌注损伤、急性呼吸窘迫综合征、细菌感染引起的休克、糖尿病或转移等。
  • [EN] METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT D'INFECTIONS DE TYPE CHOC CYTOKINIQUE, NOTAMMENT LA COVD-19, PAR INHIBITION DE L'INTERACTION CCR5/CCL5
    申请人:INCELLDX INC
    公开号:WO2021222069A1
    公开(公告)日:2021-11-04
    Methods of treating a subject suffering from COVID-19 are provided. Aspects of the methods including administering to the subject an effective amount of an inhibitor of CCR5/CCL5 interaction, such as a CCR5 antagonist. Also provided are methods of assessing severity of a disease involving hypercytokinemia, such as COVID-19, by determining the level of CCL5/RANTES in a subject, as well as compositions for use in such methods.
查看更多